NVRO250117C5000
- 0.15
- 0.000.00%
Nevro Newsroom
RBC Capital Remains a Hold on Nevro Corp (NVRO)
Where Nevro Stands With Analysts
Nevro Is Maintained at Hold by Truist Securities
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4.7
Nevro Price Target Lowered to $4.70 From $7 at Truist
Express News | Nevro Corp : Truist Securities Cuts Target Price to $4.7 From $7
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Mizuho Securities Maintains Nevro(NVRO.US) With Hold Rating, Announces Target Price $6
Here's Why You Should Retain Nevro Stock in Your Portfolio Now
Citigroup Maintains Neutral on Nevro, Lowers Price Target to $5
Nevro Is Maintained at Equal-Weight by Wells Fargo
Citi Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $5
Zacks.com Featured Highlights Include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX
Nevro Is Maintained at Hold by Canaccord Genuity
Nevro Price Target Cut to $4.00/Share From $7.00 by Canaccord Genuity
Wells Fargo Upgrades Nevro(NVRO.US) to Hold Rating, Cuts Target Price to $5
Express News | Wells Fargo Reinstates Equal-Weight on Nevro, Announces $5 Price Target
Nevro Corp: Hold Rating Amid Market Challenges and Strategic Uncertainty
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks